SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SRPT is not a good buy right now for an impatient buyer. The stock is still in a clear bearish trend (SMA200>SMA20>SMA5 with a worsening negative MACD), hedge funds are aggressively reducing exposure, and the latest reported quarter showed declining revenue and sharply wider losses. While the 3-year EMBARK data is a meaningful positive, the market is still treating the name as a “show-me” story (mixed ratings, guidance concerns). At $20.34 the stock is sitting on first support ($20.32); that can bounce, but the setup is not strong enough to justify a fresh buy without a trend reversal (e.g., reclaiming ~$22.07 pivot and improving momentum).
Price/Trend: Bearish structure with moving averages stacked negatively (SMA200 > SMA20 > SMA5), aligning with the regular-session -4.21% drop. Momentum: MACD histogram at -0.161 and negatively expanding implies downside momentum is strengthening, not stabilizing. RSI: RSI(6)=34.33 is weak and approaching oversold, suggesting a possible short-term bounce risk, but not a confirmed reversal. Key levels: Immediate support S1=20.322 (price ~20.34 is essentially sitting on it). If that fails, next support S2=19.241. Upside reversal/decision level is Pivot=22.071; resistance above at R1=23.821. Quant pattern read-through: Similar-pattern stats imply modest next-day upside odds, but negative bias over the next week/month (-1.61% week, -0.38% month), which fits the broader downtrend.
argue the prior selloff was overdone and see upside from potential broader adoption/re-approval scenarios.
centered on skepticism of EMBARK’s structural comparability and the lack of durable randomized control beyond year one.
on 2026-02-26 after hours can create downside if sales/updates disappoint.
Latest quarter: 2025/Q3. Revenue: $399.356M, down -14.52% YoY (negative growth trend). Profitability: Net income -$179.947M (loss widened sharply YoY), EPS -1.8 (worse YoY). Margins: Gross margin 62.08%, down -22.63% YoY. Read: The quarter shows weakening top-line and significantly deteriorating earnings/margins, which is inconsistent with a ‘buy now’ setup unless momentum and guidance inflect upward.
Recent trend: Ratings/targets are mixed and clustered around ‘neutral/market perform’ in the ~$20–$22 zone, with notable dispersion. Upward revisions/constructive notes: Baird raised PT to $22 (Neutral) after EMBARK 3-year data; Wedbush initiated Outperform PT $32; Mizuho upgraded to Outperform PT $26; Bernstein moved PT to $20 (Market Perform). Neutral initiations: Barclays assumed coverage Equal Weight PT $20. Bear case: H.C. Wainwright reiterates Sell with PT $5, arguing the EMBARK dataset remains structurally unreliable. Wall Street pros vs cons: Pros focus on EMBARK durability signals and potential commercial re-acceleration; cons focus on study-design skepticism, guidance risk, and business fundamentals currently trending the wrong way. Influential/politician trading: No recent congress trading data available; insiders reported as neutral with no significant recent trend.
